<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536666</url>
  </required_header>
  <id_info>
    <org_study_id>P-CKD-01</org_study_id>
    <secondary_id>EudraCT No.: 2007-000765-37</secondary_id>
    <nct_id>NCT00536666</nct_id>
  </id_info>
  <brief_title>A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients</brief_title>
  <official_title>A Non-Comparative Open-Label Study of Iron Oligosaccharide in Chronic Kidney Disease Patients With a Need for Parenteral Iron</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety profile of iron oligosaccharide in&#xD;
      patients with chronic kidney disease with a need for parenteral iron.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron dextrans have been marketed for more than 50 years and the compiled preclinical and&#xD;
      clinical experience with iron dextrans in general is well established. Pharmacosmos A/S&#xD;
      already markets the iron dextran CosmoFer® worldwide, except in the US where the product is&#xD;
      named INFeD®. A new iron oligosaccharide has been manufactured by Pharmacosmos A/S and it is&#xD;
      a further development of CosmoFer® where ferric hydroxide has been combined with low&#xD;
      molecular weight oligosaccharides in a relatively strong complex. This iron carbohydrate&#xD;
      complex builds on the well established efficacy and safety profile of existing iron dextran&#xD;
      but with a significantly reduced anaphylactic potential.&#xD;
&#xD;
      In order to ensure that iron oligosaccharide will not lead to unexpected adverse events the&#xD;
      existing clinical information on iron dextrans in general needs to be supplied with clinical&#xD;
      safety data from a limited number of relevant patients exposed to iron oligosaccharide in&#xD;
      open label non-comparator studies.&#xD;
&#xD;
      The primary objective of the present study is to obtain such safety reassurance with the use&#xD;
      of iron oligosaccharide given either as repeated IV boluses or as total dose infusion for&#xD;
      correction/maintenance therapy of anaemia in patients with chronic kidney disease with a need&#xD;
      for parenteral iron due to either absolute or functional iron deficiency anaemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AE) (Number and type of AE)</measure>
    <time_frame>Eight weeks after enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>Eight weeks after enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>At screening visit and at end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>At every visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests (biochemistry, haematology)</measure>
    <time_frame>At every visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in haemoglobin, haematocrit, s-iron, transferrin saturation, and ferritin levels</measure>
    <time_frame>At every visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Anemia, Iron-Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Iron oligosaccharide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron oligosaccharide</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>MonoFer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Chronic kidney disease patients in pre-dialysis or undergoing dialysis not currently&#xD;
        treated with parenteral iron may be included if they meet the following criteria:&#xD;
&#xD;
          -  ≥ 18 years of age at screening&#xD;
&#xD;
          -  Hb &lt; 110 g/L (6.8 mmol/L)&#xD;
&#xD;
          -  Serum ferritin &lt; 800 µgram/L&#xD;
&#xD;
          -  Life expectancy beyond 12 months&#xD;
&#xD;
          -  Willingness to participate after written informed consent&#xD;
&#xD;
        Chronic kidney disease patients in pre-dialysis or undergoing dialysis willing to switch&#xD;
        their current parenteral iron maintenance therapy to iron oligosaccharide may be included&#xD;
        if they meet the following criteria:&#xD;
&#xD;
          -  ≥ 18 years of age at screening&#xD;
&#xD;
          -  Hb ≤ 130 g/L&#xD;
&#xD;
          -  Serum ferritin &gt; 200 µgram/L but &lt; 800 µgram/L&#xD;
&#xD;
          -  Life expectancy beyond 12 months&#xD;
&#xD;
          -  Willingness to participate after written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non iron deficiency anaemia&#xD;
&#xD;
          -  Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis,&#xD;
             haemosiderosis)&#xD;
&#xD;
          -  Drug hypersensitivity (i.e. previous hypersensitivity to iron dextran or iron mono- or&#xD;
             disaccharide complexes)&#xD;
&#xD;
          -  Patients with a history of multiple allergies.&#xD;
&#xD;
          -  Decompensated liver cirrhosis and hepatitis (alanine aminotransferase &gt; 3 times&#xD;
             normal).&#xD;
&#xD;
          -  Acute or chronic infections&#xD;
&#xD;
          -  Rheumatoid arthritis with symptoms or signs of active inflammation&#xD;
&#xD;
          -  Pregnancy and nursing. To avoid pregnancy, women have to be postmenopausal, surgically&#xD;
             sterile, sexually inactive or practice reliable contraception&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Planned elective surgery during the study where significant blood loss is expected&#xD;
&#xD;
          -  Participation in any other clinical trial within three months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soeren Ladefoged, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Nefrologisk afdeling P</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, Nefrologisk afdeling P</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <last_update_submitted>October 7, 2008</last_update_submitted>
  <last_update_submitted_qc>October 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2008</last_update_posted>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Aneamia</keyword>
  <keyword>Iron oligosaccharide</keyword>
  <keyword>Chronic kidney disease patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

